Gerolami A, Sarles H, Brette R, Paraf A, Rautureau J, Debray C, Bermann C, Etienne J P, Chaput J C, Petite J P
Digestion. 1977;16(4):299-307. doi: 10.1159/000198082.
134 patients with radiolucent gallstones were randomly allocated to receive either placebo or 1 of 3 different doses of chenodeoxycholic acid (CDCA); 750, 1,500, or 3,000 mg). The initial dose was lowered if not well tolerated. 107 patients were treated for more than 3 months. Among them, stones dissolved in 21 and were smaller in 25 patients. Partial or complete dissolution occurred in 4 of the 13 receiving 375 mg/day, 14 of 37 receiving 750 mg, 24 of the 38 receiving 1,500 mg and 4 of 8 receiving 3,000 mg/day. The number of responders to the therapy was significantly greater in the groups of patients receiving 1,500 mg/day or 17-24 mg/kg body weight than in any other group. However, side effects, i.e., diarrhea and transaminase increase, are also dose related. It appears from this study that the optimal dose of CDCA may be between 17 and 20 mg/kg body weight.
134例有透光性胆结石的患者被随机分配接受安慰剂或3种不同剂量鹅去氧胆酸（CDCA）中的一种（750、1500或3000毫克）。若耐受性不佳则降低初始剂量。107例患者接受治疗超过3个月。其中，21例患者结石溶解，25例患者结石变小。接受375毫克/天的13例患者中有4例部分或完全溶解，接受750毫克的37例患者中有14例，接受1500毫克的38例患者中有24例，接受3000毫克/天的8例患者中有4例。接受1500毫克/天或17 - 24毫克/千克体重的患者组中治疗反应者的数量显著多于其他任何组。然而，副作用，即腹泻和转氨酶升高，也与剂量相关。从这项研究来看，CDCA的最佳剂量可能在17至20毫克/千克体重之间。
